Evaluating the rapid onset of analgesic efficacy of a novel calcium fructoborate complex (BRAVOFLEX®) in subjects with knee discomfort: A clinical analysis

Abstract

The clinical management of joint discomfort typically involves long-term administration of glucosamine or chondroitin, which often require 8–12 weeks for therapeutic onset ^[1]. This paper evaluates the clinical efficacy of Bravoflex®, a nature-identical Calcium Fructoborate (CFB) complex. In a standardized clinical observation (Study 1), subjects with mild-to-moderate knee discomfort were administered 110 mg of Bravoflex® twice daily. Results demonstrated a statistically significant reduction in Western Ontario and McMaster Universities Osteoarthritis Index (WOMAC) scores within 7 to 14 days, positioning Bravoflex® as a high-bioavailability alternative for rapid joint mobility restoration.

Keywords: Calcium Fructoborate, Bravoflex®, Joint Pain, WOMAC, Boron-Carbohydrate Complex, Rapid Onset.